Cliff Asness’s Lineage Cell Therapeutics LCTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$11.6K Buy
+12,097
New +$13.4K ﹤0.01% 4046
2025
Q4
– Sell
-11,650
Closed -$19.7K – 3611
2025
Q3
$19.7K Sell
11,650
-183,733
-94% -$217K ﹤0.01% 3450
2025
Q2
$177K Buy
195,383
+163,392
+511% +$96.9K ﹤0.01% 3077
2025
Q1
$14.4K Buy
+31,991
New +$18.8K ﹤0.01% 3136
2022
Q1
– Sell
-40,688
Closed -$100K – 2253
2021
Q4
$100K Sell
40,688
-60,239
-60% -$141K ﹤0.01% 2148
2021
Q3
$254K Buy
+100,927
New +$259K ﹤0.01% 2086
2016
Q2
– Sell
-11,713
Closed -$29K – 2236
2016
Q1
$29K Sell
11,713
-31,390
-73% -$70K ﹤0.01% 2202
2015
Q4
$143K Sell
43,103
-16,050
-27% -$48K ﹤0.01% 2191
2015
Q3
$143K Buy
59,153
+5,509
+10% +$14.3K ﹤0.01% 2103
2015
Q2
$157K Buy
+53,644
New +$208K ﹤0.01% 2132

Other funds holding LCTX

Cliff Asness's LCTX Position: Q3 2026 in Review

Cliff Asness opened a new position in Lineage Cell Therapeutics (LCTX) in Q3 2026: 12,097 shares worth $11.6K. The stake represents ﹤0.01% of the portfolio and ranks #4046 among its holdings. This is a return to the name: Cliff Asness previously reported a position in LCTX as recently as Q3 2025.

Cliff Asness first reported a position in LCTX in Q2 2015 and has held it in 10 quarters since. The position peaked at $254K in Q3 2021. 140 funds tracked by Wall St. Rank hold LCTX as of Q3 2026.

  • Cliff Asness held 12,097 shares of Lineage Cell Therapeutics worth $11.6K as of Q3 2026.
  • Lineage Cell Therapeutics was a new Cliff Asness position in Q3 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Cliff Asness's portfolio in Q3 2026, its #4046 holding.
  • Cliff Asness first reported a position in Lineage Cell Therapeutics in Q2 2015 and has held it in 10 quarters since.
  • Cliff Asness's Lineage Cell Therapeutics position peaked at $254K in Q3 2021.
  • 140 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2026.

Based on AQR Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.